Standard of Care Second Line Therapy
Phase 2Withdrawn 2 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Pancreatic Cancer
Conditions
Metastatic Pancreatic Cancer
Trial Timeline
Nov 1, 2016 → Aug 30, 2018
NCT ID
NCT02967770About Standard of Care Second Line Therapy
Standard of Care Second Line Therapy is a phase 2 stage product being developed by Caris Life Sciences for Metastatic Pancreatic Cancer. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02967770. Target conditions include Metastatic Pancreatic Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Pancreatic Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02967770 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Metastatic Pancreatic Cancer